These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
210 related articles for article (PubMed ID: 25077772)
21. An EGFR ligand promotes EGFR-mutant but not KRAS-mutant lung cancer in vivo. Tomoshige K; Guo M; Tsuchiya T; Fukazawa T; Fink-Baldauf IM; Stuart WD; Naomoto Y; Nagayasu T; Maeda Y Oncogene; 2018 Jul; 37(28):3894-3908. PubMed ID: 29662194 [TBL] [Abstract][Full Text] [Related]
22. Genetic Evidence for XPC-KRAS Interactions During Lung Cancer Development. Zhang X; He N; Gu D; Wickliffe J; Salazar J; Boldogh I; Xie J J Genet Genomics; 2015 Oct; 42(10):589-596. PubMed ID: 26554912 [TBL] [Abstract][Full Text] [Related]
23. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice. Hermann PC; Sancho P; Cañamero M; Martinelli P; Madriles F; Michl P; Gress T; de Pascual R; Gandia L; Guerra C; Barbacid M; Wagner M; Vieira CR; Aicher A; Real FX; Sainz B; Heeschen C Gastroenterology; 2014 Nov; 147(5):1119-33.e4. PubMed ID: 25127677 [TBL] [Abstract][Full Text] [Related]
25. Targeting UHRF1-dependent DNA repair selectively sensitizes KRAS mutant lung cancer to chemotherapy. Tian D; Tang J; Geng X; Li Q; Wang F; Zhao H; Narla G; Yao X; Zhang Y Cancer Lett; 2020 Nov; 493():80-90. PubMed ID: 32814087 [TBL] [Abstract][Full Text] [Related]
26. Vaccine therapy of established tumors in the absence of autoimmunity. Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742 [TBL] [Abstract][Full Text] [Related]
27. Identification of a ras oncogene peptide that contains both CD4(+) and CD8(+) T cell epitopes in a nested configuration and elicits both T cell subset responses by peptide or DNA immunization. Bristol JA; Orsini C; Lindinger P; Thalhamer J; Abrams SI Cell Immunol; 2000 Nov; 205(2):73-83. PubMed ID: 11104579 [TBL] [Abstract][Full Text] [Related]
28. Modulation of Mutant Zhou X; Padanad MS; Evers BM; Smith B; Novaresi N; Suresh S; Richardson JA; Stein E; Zhu J; Hammer RE; O'Donnell KA Mol Cancer Res; 2019 Feb; 17(2):594-603. PubMed ID: 30409919 [TBL] [Abstract][Full Text] [Related]
29. Mutant Hras(G12V) and Kras(G12D) have overlapping, but non-identical effects on hepatocyte growth and transformation frequency in transgenic mice. Figueiredo ML; Stein TJ; Jochem A; Sandgren EP Liver Int; 2012 Apr; 32(4):582-91. PubMed ID: 22221894 [TBL] [Abstract][Full Text] [Related]
30. Targeting glycan sulfation in a CD11c+ myeloid population inhibits early KRAS-mutant lung neoplasia. Kim SY; Johns SC; Gupta P; Varki N; Fuster MM Neoplasia; 2021 Nov; 23(11):1137-1143. PubMed ID: 34715561 [TBL] [Abstract][Full Text] [Related]
31. Endoplasmic reticulum chaperone GRP78/BiP is critical for mutant Kras-driven lung tumorigenesis. Rangel DF; Dubeau L; Park R; Chan P; Ha DP; Pulido MA; Mullen DJ; Vorobyova I; Zhou B; Borok Z; Offringa IA; Lee AS Oncogene; 2021 May; 40(20):3624-3632. PubMed ID: 33931739 [TBL] [Abstract][Full Text] [Related]
32. Targeting ST2 expressing activated regulatory T cells in Kras-mutant lung cancer. Kim BS; Clinton J; Wang Q; Chang SH Oncoimmunology; 2020; 9(1):1682380. PubMed ID: 32002289 [TBL] [Abstract][Full Text] [Related]
33. Kirsten Ras* oncogene: significance of its discovery in human cancer research. Tsuchida N; Murugan AK; Grieco M Oncotarget; 2016 Jul; 7(29):46717-46733. PubMed ID: 27102293 [TBL] [Abstract][Full Text] [Related]
34. Cis-acting genomic elements of the Pas1 locus control Kras mutability in lung tumors. Manenti G; Trincucci G; Pettinicchio A; Amendola E; Scarfò M; Dragani TA Oncogene; 2008 Sep; 27(43):5753-8. PubMed ID: 18560355 [TBL] [Abstract][Full Text] [Related]
35. Scrib heterozygosity predisposes to lung cancer and cooperates with KRas hyperactivation to accelerate lung cancer progression in vivo. Elsum IA; Yates LL; Pearson HB; Phesse TJ; Long F; O'Donoghue R; Ernst M; Cullinane C; Humbert PO Oncogene; 2014 Nov; 33(48):5523-33. PubMed ID: 24276238 [TBL] [Abstract][Full Text] [Related]
36. Specific and Efficient Regression of Cancers Harboring KRAS Mutation by Targeted RNA Replacement. Kim SJ; Kim JH; Yang B; Jeong JS; Lee SW Mol Ther; 2017 Feb; 25(2):356-367. PubMed ID: 28153088 [TBL] [Abstract][Full Text] [Related]
37. Targeting KRAS mutation-bearing lung cancer in vivo by pulmonary surfactant-adenovirus-mediated gene transfer. Fukazawa T; Maeda Y; Matsuoka J; Ono T; Mominoki K; Yamatsuji T; Shigemitsu K; Morita I; Murakami I; Tanaka H; Durbin ML; Naomoto Y Anticancer Res; 2010 Dec; 30(12):4925-35. PubMed ID: 21187472 [TBL] [Abstract][Full Text] [Related]
38. [Specific immune against pancreatic cancer induced by dendritic cells pulsed with mutant K-ras peptide]. Yang B; He Y; Sun DL; Zou Y; Qin XH; Huang BH Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(28):1956-60. PubMed ID: 19062734 [TBL] [Abstract][Full Text] [Related]